Goldman Sachs analysts note that the garadacimab (CSL312) product has the potential to be a "pipeline in a product" thanks to multiple end use possibilities.
CSL312 is a humanised anti-factor XIIa monoclonal antibody in development for multiple indications including as a subcutaneous therapy for HAE, with the potential for administration every 4 weeks (vs. every 2-3 days for Haegarda). Given its early position in the coagulation cascade, there is also potential application in various other disorders (including fibrosis, cardiovascular and inflammatory indications).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$257.38 |
Change
8.990(3.62%) |
Mkt cap ! $124.6B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $258.31 | $251.10 | $370.9M | 1.440M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $257.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $257.38 | 3331 | 1 |
View Market Depth
| Last trade - 16.11pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |